Ongoing litigation against AbbVie and Capstone Therapeutics remains a factor, though management provided no specific updates on the proceedings. A $70.3 million annual revenue decrease reflects the ...

Phase 2 third cohort (28 days, 15 mg) generally safe and well toleratedARCT-032 permitted to proceed into 12-week Phase 2 study; dosing to begin H1 2026Cash runway extended into Q2 2028Investor ...

A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.